Impax Asset Management Group plc Decreases Position in Johnson & Johnson (NYSE:JNJ)

Impax Asset Management Group plc cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,018 shares of the company's stock after selling 4,333 shares during the period. Impax Asset Management Group plc's holdings in Johnson & Johnson were worth $10,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC raised its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 22.0% in the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock worth $2,885,000 after buying an additional 3,594 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $1,339,878,000. Finally, Banco Santander S.A. grew its stake in Johnson & Johnson by 31.0% in the fourth quarter. Banco Santander S.A. now owns 40,803 shares of the company's stock worth $5,901,000 after purchasing an additional 9,664 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Bank of America dropped their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Up 0.2%

Johnson & Johnson stock opened at $155.90 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market capitalization of $375.11 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business has a fifty day moving average price of $153.68 and a 200-day moving average price of $154.17.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.